The Effects of Exenatide Once Weekly (EXQW) and Exenatide Twice a Day (EXBID) on Beta-Cell Function in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
Background. In patients with type 2 diabetes mellitus (T2DM) and poor glycemic control receiving metformin (MET), glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are recommended as the adjunctive therapy. However, there are only a few studies involving the comparative effects of exenatide twic...
Saved in:
Main Authors: | Jie Wang, Xinye Jin, Ping An, Songyan Yu, Yiming Mu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-01-01
|
Series: | Journal of Diabetes Research |
Online Access: | http://dx.doi.org/10.1155/2019/8083417 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus
by: Jie Zhang, et al.
Published: (2022-01-01) -
Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance
by: Xuan Du, et al.
Published: (2018-01-01) -
Study of Postprandial Lipaemia in Type 2 Diabetes Mellitus: Exenatide versus Liraglutide
by: Maria Voukali, et al.
Published: (2014-01-01) -
Exenatide Is an Effective Antihyperglycaemic Agent in a Mouse Model of Wolfram Syndrome 1
by: Tuuli Sedman, et al.
Published: (2016-01-01) -
Action Mechanisms of Metformin Combined with Exenatide and Metformin Only in the Treatment of PCOS in Obese Patients
by: Jingwen Gan, et al.
Published: (2023-01-01)